{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:12:15Z","timestamp":1765807935588},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00277-021-04555-3","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:02:55Z","timestamp":1620950575000},"page":"2061-2070","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma patients\u2014a single-center retrospective study"],"prefix":"10.1007","volume":"100","author":[{"given":"Bernard","family":"Regidor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa-Skye","family":"Goldwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Bujarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Swift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Eades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsiye","family":"Emamy-Sadr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrooz","family":"Eshagian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"4555_CR1","doi-asserted-by":"publisher","first-page":"v155","DOI":"10.1093\/annonc\/mdq178","volume":"21","author":"J-L Harousseau","year":"2010","unstructured":"Harousseau J-L, Dreyling M (2010) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v155\u2013v157. https:\/\/doi.org\/10.1093\/annonc\/mdq178","journal-title":"Ann Oncol"},{"key":"4555_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Richardson PG, Moreau P, Anderson KC (2014) Current treatment landscape for relapsed and\/or refractory multiple myeloma. Nat Rev Clin Oncol 12:42\u201354. https:\/\/doi.org\/10.1038\/nrclinonc.2014.200","journal-title":"Nat Rev Clin Oncol"},{"key":"4555_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nrc952","volume":"2","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927\u2013937. https:\/\/doi.org\/10.1038\/nrc952","journal-title":"Nat Rev Cancer"},{"key":"4555_CR4","unstructured":"AbbVie, Inc., Genentech, Inc. Venclexta (venetoclax) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s013lbl.pdf. Accessed 28 Oct 2020"},{"key":"4555_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2017013334","volume":"2","author":"M Merz","year":"2017","unstructured":"Merz M, Jauch A, Hielscher T et al (2017) Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv 2:1\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2017013334","journal-title":"Blood Adv"},{"key":"4555_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1200\/JCO.2000.18.4.804","volume":"18","author":"R K\u00f6nigsberg","year":"2000","unstructured":"K\u00f6nigsberg R, Zojer N, Ackermann J et al (2000) Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 18:804\u2013812. https:\/\/doi.org\/10.1200\/JCO.2000.18.4.804","journal-title":"J Clin Oncol"},{"key":"4555_CR7","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Blood EA, Oken MM et al (2002) Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99:3735\u20133741. https:\/\/doi.org\/10.1182\/blood.V99.10.3735","journal-title":"Blood"},{"key":"4555_CR8","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C et al (2017) Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130:2401\u20132409. https:\/\/doi.org\/10.1182\/blood-2017-06-788786","journal-title":"Blood"},{"key":"4555_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.clml.2018.06.003","volume":"18","author":"KJ Rahbari","year":"2018","unstructured":"Rahbari KJ, Nosrati JD, Spektor TM, Berenson JR (2018) Venetoclax in combination with bortezomib, dexamethasone and daratumumab for multiple myeloma. Clin Lymphoma Myeloma Leuk 18:339\u2013343. https:\/\/doi.org\/10.1016\/j.clml.2018.06.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4555_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2019-124407","volume":"134","author":"N Bahlis","year":"2019","unstructured":"Bahlis N, Baz R, Harrison S et al (2019) First analysis from a phase 1\/2 study of venetoclax in combination with daratumumab and dexamethasone, +\/- bortezomib, in patients with relapsed\/refractory multiple myeloma. Blood 134:925. https:\/\/doi.org\/10.1182\/blood-2019-124407","journal-title":"Blood"},{"key":"4555_CR11","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW et al (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood 130:2392\u20132400. https:\/\/doi.org\/10.1182\/blood-2017-06-788323","journal-title":"Blood"},{"key":"4555_CR12","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncol 21:1630\u20131642. https:\/\/doi.org\/10.1016\/s1470-2045(20)30525-8","journal-title":"The Lancet Oncol"},{"key":"4555_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV (2008) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3\u20139. https:\/\/doi.org\/10.1038\/leu.2008.291","journal-title":"Leukemia"},{"key":"4555_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3324\/haematol.2019.232330","volume":"105","author":"S Kovacs","year":"2019","unstructured":"Kovacs S, Luan J, Dold S, Weis A et al (2019) Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient. Haematologica 105:138\u2013140. https:\/\/doi.org\/10.3324\/haematol.2019.232330","journal-title":"Haematologica"},{"key":"4555_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165\u2013172. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05188.x","journal-title":"Br J Haematol"},{"key":"4555_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2141.2011.08884.x","volume":"155","author":"JR Berenson","year":"2011","unstructured":"Berenson JR, Yellin O, Chen C, Patel R et al (2011) A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol 155:580\u2013587. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08884.x","journal-title":"Br J Haematol"},{"key":"4555_CR17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1200\/jco.2005.03.2383","volume":"24","author":"JR Berenson","year":"2006","unstructured":"Berenson JR, Yang HH, Sadler K, Jarutirasarn SG et al (2006) Phase I\/II Trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937\u2013944. https:\/\/doi.org\/10.1200\/jco.2005.03.2383","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04555-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:09:59Z","timestamp":1626412199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04555-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4555"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04555-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board, and all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All patients provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki 1964 and its later amendments and International Conference on Harmonization Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This retrospective study was approved by the institutional review board to proceed without patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JRB receives research support from Takeda and speaker fees from Takeda and Janssen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}